Evommune, Inc. (NYSE:EVMN) Receives $45.71 Consensus Price Target from Brokerages

Shares of Evommune, Inc. (NYSE:EVMN) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $49.6667.

A number of brokerages recently commented on EVMN. Raymond James Financial started coverage on Evommune in a research note on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 price objective for the company. Oppenheimer started coverage on shares of Evommune in a research note on Thursday, January 22nd. They set an “outperform” rating and a $42.00 price objective on the stock. Zacks Research upgraded shares of Evommune to a “hold” rating in a report on Tuesday, December 2nd. William Blair started coverage on shares of Evommune in a report on Monday, December 1st. They issued an “outperform” rating on the stock. Finally, Weiss Ratings initiated coverage on shares of Evommune in a research report on Tuesday, February 3rd. They set a “sell (e)” rating on the stock.

Evommune Price Performance

EVMN opened at $28.40 on Friday. The firm’s 50 day moving average is $20.19. The company has a market capitalization of $895.28 million and a PE ratio of -3.52. Evommune has a one year low of $13.89 and a one year high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $10.00 million.

Institutional Investors Weigh In On Evommune

Several large investors have recently modified their holdings of the business. EQT Fund Management S.a r.l. bought a new position in shares of Evommune during the 4th quarter valued at about $84,395,000. RA Capital Management L.P. bought a new position in Evommune in the fourth quarter valued at approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in shares of Evommune in the fourth quarter valued at approximately $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in shares of Evommune during the fourth quarter worth $24,670,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Evommune during the fourth quarter worth $22,408,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.